Ovid Therapeutics Reports Q1 2025 Financial Results

Ovid Therapeutics ( (OVID) ) has released its Q1 earnings. Here is a breakdown of the information Ovid Therapeutics presented to its investors.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs. In its latest earnings report for the quarter ending March 31, 2025, Ovid Therapeutics highlighted a net loss of $10.2 million, a slight improvement from the $11.7 million loss in the same period last year. The company reported total revenue of $130,000, primarily from licensing agreements, and noted a decrease in operating expenses, which stood at $12.7 million compared to $17.6 million in the previous year. Ovid’s cash and cash equivalents totaled $21.1 million, with marketable securities valued at $21.9 million, indicating a solid liquidity position. Looking ahead, Ovid Therapeutics remains focused on securing additional funding and advancing its pipeline of drug candidates, with management expressing confidence in sustaining operations for at least the next 12 months.